Viridian Therapeutics Financials
| 0K1R Stock | 14.98 0.32 2.09% |
Viridian | Select Account or Indicator |
Understanding current and past Viridian Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Viridian Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Viridian Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Viridian Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Viridian Therapeutics. Check Viridian Therapeutics' Beneish M Score to see the likelihood of Viridian Therapeutics' management manipulating its earnings.
Viridian Therapeutics Stock Summary
Viridian Therapeutics competes with Hansa Investment, Caledonia MiningPlc, Livermore Investments, Mercantile Investment, and Beowulf Mining. Viridian Therapeutics is entity of United Kingdom. It is traded as Stock on LSE exchange.Specialization | Industrials, Commercial & Professional Services |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| Business Address | 221 Crescent Street, |
| Sector | Commercial Services & Supplies |
| Industry | Industrials |
| Benchmark | Dow Jones Industrial |
| Website | www.viridiantherapeutics.com |
| Phone | 617 272 4600 |
You should never invest in Viridian Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Viridian Stock, because this is throwing your money away. Analyzing the key information contained in Viridian Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Viridian Therapeutics Key Financial Ratios
There are many critical financial ratios that Viridian Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Viridian Therapeutics reports annually and quarterly.| Revenue | 302 K | ||||
| Gross Profit | (237.95 M) | ||||
| EBITDA | (266.36 M) | ||||
| Net Income | (269.95 M) | ||||
| Total Asset | 742.4 M |
Viridian Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 131.3M | 203.7M | 435.1M | 490.4M | 742.4M | 779.5M | |
| Other Current Liab | 9.2M | 10.5M | 18.2M | 23.3M | 44.9M | 47.2M | |
| Net Debt | (45.4M) | (41.8M) | (150.3M) | (81.8M) | (78.5M) | (74.6M) | |
| Retained Earnings | (278.9M) | (358.3M) | (488.2M) | (725.9M) | (995.9M) | (946.1M) | |
| Accounts Payable | 670K | 2.3M | 14.2M | 2.2M | 2.1M | 2.1M | |
| Cash | 45.9M | 42.3M | 155.6M | 102.8M | 99.6M | 104.6M | |
| Net Receivables | 24K | 108K | 451K | 102K | 91.8K | 87.2K | |
| Other Current Assets | 2.0M | 2.6M | 6.5M | 9.0M | 20.9M | 21.9M | |
| Total Liab | 11.2M | 16.0M | 40.0M | 48.4M | 70.8M | 74.3M | |
| Total Current Assets | 129.6M | 200.2M | 424.6M | 486.5M | 738.5M | 775.4M | |
| Short Term Debt | 455K | 520K | 613K | 843K | 513K | 487.4K | |
| Common Stock | 42K | 239K | 414K | 540K | 810K | 850.5K | |
| Net Tangible Assets | 15.8M | (60.8M) | 53.9M | 252.9M | 290.9M | 305.4M |
Viridian Therapeutics Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 508K | 3K | 486K | 1.8M | 3.0M | 3.2M | |
| Total Revenue | 1.1M | 3.0M | 1.8M | 314K | 302K | 286.9K | |
| Gross Profit | (27.3M) | 2.3M | 1.0M | (1.0M) | 302K | 317.1K | |
| Operating Income | (110.4M) | (79.7M) | (134.3M) | (254.5M) | (299.0M) | (284.1M) | |
| Ebit | (110.2M) | (79.4M) | (129.4M) | (235.1M) | (266.9M) | (253.6M) | |
| Research Development | 28.3M | 56.9M | 100.9M | 159.8M | 238.3M | 250.2M | |
| Ebitda | (109.7M) | (78.8M) | (128.6M) | (234.6M) | (266.4M) | (253.0M) | |
| Cost Of Revenue | 28.3M | 620K | 755K | 1.3M | 1.5M | 1.4M | |
| Income Before Tax | (110.7M) | (79.4M) | (129.9M) | (237.7M) | (269.9M) | (256.5M) | |
| Net Income | (111.0M) | (79.4M) | (125.4M) | (237.7M) | (269.9M) | (256.5M) | |
| Income Tax Expense | 269K | 3K | (4.4M) | 18.6M | 21.3M | 22.4M |
Viridian Therapeutics Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 21.1M | (3.6M) | 113.3M | (52.8M) | (3.2M) | (3.1M) | |
| Free Cash Flow | (29.8M) | (54.9M) | (94.6M) | (185.1M) | (232.8M) | (221.2M) | |
| Depreciation | 239K | 120K | 255K | 522K | 600.3K | 630.3K | |
| Other Non Cash Items | 72.6M | 7.5M | 54K | (4.7M) | (4.5M) | (4.3M) | |
| Capital Expenditures | 42K | 338K | 797K | 898K | 511K | 327.0K | |
| Net Income | (110.7M) | (79.4M) | (129.9M) | (237.7M) | (269.9M) | (256.5M) | |
| End Period Cash Flow | 45.9M | 42.3M | 155.6M | 102.8M | 99.6M | 104.6M | |
| Investments | 28.3M | (79.8M) | (74.0M) | (114.3M) | (102.9M) | (97.8M) | |
| Change To Netincome | 3.9M | 76.0M | 22.9M | 19.8M | 22.8M | 20.3M |
Viridian Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Viridian Therapeutics's current stock value. Our valuation model uses many indicators to compare Viridian Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Viridian Therapeutics competition to find correlations between indicators driving Viridian Therapeutics's intrinsic value. More Info.Viridian Therapeutics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viridian Therapeutics' earnings, one of the primary drivers of an investment's value.Viridian Therapeutics Systematic Risk
Viridian Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Viridian Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Viridian Therapeutics correlated with the market. If Beta is less than 0 Viridian Therapeutics generally moves in the opposite direction as compared to the market. If Viridian Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Viridian Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Viridian Therapeutics is generally in the same direction as the market. If Beta > 1 Viridian Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Viridian Therapeutics Total Assets Over Time
Viridian Therapeutics March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Viridian Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Viridian Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Viridian Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Viridian Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Viridian Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 15.94 | |||
| Value At Risk | (5.39) | |||
| Potential Upside | 5.65 |
Additional Tools for Viridian Stock Analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.